filmov
tv
Cancer immunotherapy | The PD-L1 pathway
Показать описание
The role of the immune system is to protect the body from foreign invaders. In responding to cancer, T cells play a central role in the immune system. Programmed death ligand 1 (PD-L1) is one of the inhibitory ligands that, under normal conditions, help maintain immune homeostasis. In many cancers, however, PD-L1 can help tumour cells evade immune system surveillance.
Get in touch with us:
Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
Get in touch with us:
Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
0:02:12
Cancer immunotherapy | The PD-L1 pathway
0:04:00
Cancer Immunotherapy - PD-1 and PD-L1
0:04:27
Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers
0:01:16
Explaining Immunotherapy, PD-L1 and PD-1
0:03:29
PD-L1/PD-1 Pathway: A Security Checkpoint
1:02:49
PD-L1/PD-1 Cancer Immunotherapy and New Targets - Gordon Freeman, PhD
0:02:47
PD-L1 – Immunotherapy: Unleashing the body to fight cancer | Dana-Farber Cancer Institute
0:12:55
Patients with High PD-L1: Immunotherapy Alone or Combine with Chemo? - ASCO Lung Review 2022
0:48:04
AON 2024 | Antibody-Drug Conjugates in Lung Cancer — Edward B Garon, MD, MS
0:01:20
How does PD-L1 impact treatment options for lung cancer?
0:05:02
Going beyond PD-L1 testing for lung cancer immunotherapy
0:05:33
Cancer Immune Checkpoint Inhibitors
0:02:40
Efficacy Of PDL1 Inhibitors & Immunotherapy In Lung Cancer | Dr. Suresh Babu M.C | Doctors'...
0:02:44
How is Immunotherapy Used to Fight Cancer? | Dana-Farber Cancer Institute | Science Illustrated
0:04:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
0:00:50
PD-1 and PD-L1 Receptors: Key players in immunotherapy 🎗️🔬
0:01:42
Dr. Desai on Immunotherapy in Patients With NSCLC and Low PD-L1 Expression
0:03:50
The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response?
0:02:57
Car brakes: PD-1/PD-L1 molecular pathway explained
0:03:12
Understanding PD-L1 and Its Role in Lung Cancer Immunotherapy
0:23:02
Immunotherapy: Moving beyond PD1 and PDL1 inhibitors
0:18:58
PD-L1 Testing by Immunohistochemistry
0:36:47
The Status of PD-L1 Testing and What is Next? | Presented by Dr. Ming Tsao
0:06:09
Cancer Immunotherapy- PD1 and PDL1 interaction
Комментарии